fazirsiran   Click here for help

GtoPdb Ligand ID: 14727

Synonyms: ADS-001 | ADS001 | ARO-AAT
Compound class: Nucleic acid
Comment: Fazirsiran (ADS-001) is a small interfering RNA (siRNA) that is designed to target the mRNA that would otherwise be translated into a mutant, misfolded and aggregating version of the AAT protein (known as Z-AAT which is transcribed from the mutant SERPINA1 PI*ZZ allele) in patients with alpha-1 antitrypsin deficiency [2-4].
To improve pharmacokinetics, the nucleotides are chemically modified (2'-O-methyl/2'-MOE and 2'-deoxy-2'-fluoro/2'-F monomers), with a mixed phosphorothioate/phosphate backbone, and it has sugar modifications at both ends of the forward strand to enhance hepatic delivery via binding to liver-expressed asialoglycoprotein receptors (ASGRs).
No information available.
Summary of Clinical Use Click here for help
Fazirsiran (ADS-001, ARO-AAT) was progressed as a clinical candidate to evelaute its potential to treat alpha-1-antitrypsin deficiency.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05677971 Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein Phase 3 Interventional Takeda
NCT06165341 Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) Phase 3 Interventional Takeda
NCT03945292 Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) Phase 2 Interventional Arrowhead Pharmaceuticals The SEQUOIA study 1